Peptide receptor radionuclide therapy

Clinical Nuclear Medicine

Volumn , Issue , 2007, Pages 443-455

  Teunissen, J J M ^a   Kwekkeboom, D J ^a   De Jong, M ^a   Esser, J P ^a   Valkema, R ^a   Krenning, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68949094951     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-28026-2_24     Document Type: Chapter

References (72)

1. Andersson P, et al. (1996) Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1- octreotide. J Nucl Med 37(12): 2002-2006
2. Anthony LB, et al. (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32(2):123-132
3. Bakker WH, et al. (1991) In vivo application of [111In-DTPAD-Phe1]- octreotide for detection of somatostatin receptorpositive tumors in rats. Life Sci 49(22):1593-1601
4. Barone R, et al. (2004) Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 19(9):2275-2281
5. Barone R, et al. (2005) Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 (1 Suppl):99-106
6. Baum RP, et al. (2004a) Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTATyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med 31 (Suppl 2):S238 (abstract
7. Baum RP, et al. (2004b) Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner tumoren klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Der Onkologe 10(10):1098-1110
8. Béh́M, et al. (2003) Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med 44 (Suppl2):S218 (abstract
9. Bodei L, et al. (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 30(2): 207-216
10. Bodei L, et al. (2004) Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours.Eur JNuclMedMol Imaging31(7):1038-1046
11. Bruno JF, BerelowitzM(1993) Somatostatin receptors: Orphan that found family and function. Mol Cell Neurosci 4(4): 307-309
12. Buscombe JR, et al. (2003) Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 44(1):1-6
13. Bushnell D, et al. (2003a) Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive livermetastases. Cancer Biother Radiopharm 18(4):581-588
14. Bushnell D, et al. (2003b) Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 44(10):1556-1560
15. Capello A, et al. (2003) Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 44(1): 98-104
16. Chinol M, et al. (2002) Receptor-mediated radiotherapy with Y-DOTA-D-Phe-Tyr-octreotide: The experience of the European Institute of Oncology group. Semin Nucl Med 32(2): 141-147
17. Cybulla M, et al. (2001) End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 28(10):1552-1554
18. De Jong M, et al. (1996) Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 37(8):1388-1392
19. De Jong M, et al. (1998) Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58(3):437-441
20. De Jong M, et al. (2001a) Tumor response after [(90)Y-DOTA( 0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42(12):1841-1846
21. De Jong M, et al. (2001b) Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability. J Nucl Med 28(8):1026 (abstract
22. De Jong M, et al. (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32(2):133-140
23. De Jong M, et al. (2003) Radiolabelled peptides for tumour therapy: Current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30(3):463-469
24. De Jong M, et al. (2005) Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 46 (1 Suppl):13-17
25. Emami B, et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109-122
26. Hofland LJ, et al. (1995) Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 136(9):3698-3706
27. Hofland LJ, et al. (2003) Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-DPhe1] octreotide in somatostatin receptor-positive organs. J Nucl Med 44(8):1315-1321
28. Jamar F, et al. (2003) 86Y-DOTA(0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30(4):510-518
29. John M, et al. (1996) Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38(1):33-39
30. Krenning EP, et al. (1992) Somatostatin receptor scintigraphy with indium-111-DTPA-d-phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33(5):652-658
31. Krenning EP, et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20(8):716-731
32. Krenning EP, et al. (1994) Radiotherapy with a radiolabeled somatostatin analogue, [111in-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 733:496-506
33. Krenning EP, et al. (1999) Radiolabelled somatostatin analogue( s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10 (Suppl 2):S23-29
34. Kwekkeboom D, et al. (2000) Peptide receptor imaging and therapy. J Nucl Med 41(10):1704-1713
35. Kwekkeboom DJ, et al. (2001) [177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28(9):1319-1325
36. KwekkeboomDJ, et al. (2003a) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 30(3):417-422
37. Kwekkeboom DJ, et al. (2003b) Treatment with Lu-177-DOTATyr3-octreotate in patients with neuroendocrine tumors: Interim results. Eur J Nucl Med Mol Imaging 30 (Suppl 2) (Suppl 2):S231 (abstract
38. Kwekkeboom DJ, et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12): 2754-2762
39. McCarthy KE, et al. (2000) In situ radiotherapy with 111Inpentetreotide. State of the art and perspectives. Q J Nucl Med 44(1):88-95
40. Moll S, et al. (2001) A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 37(4):847-851
41. O'Donoghue JA, et al. (1995) Relationships between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med 36(10):1902-1909
42. Otte A, et al. (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351(9100):417-418
43. Otte A, et al. (1999) Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 26(11):1439-1447
44. Paganelli G, et al. (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D Phe1-Tyr3-octreotide. Eur J Nucl Med 28(4): 426-434
45. Paganelli G, et al. (2002) 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66(6):393-398
46. Panetta R, et al. (1994) Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol 45(3):417-427
47. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30(5):781-793
48. Reubi JC, et al. (1990) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to EGF receptors. Int J Cancer 46(3):416-420
49. Reubi JC, et al. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273-282
50. Reubi JC, et al. (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46 Suppl 1:67S-75S
51. Rohrer L, et al. (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci U S A 90(9):4196-4200
52. Rolleman EJ, et al. (2003) Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30(1):9-15
53. Sanders C, et al. (1998) Reporting on quality of life in randomised controlled trials: Bibliographic study. BMJ (Clinical Research ed.)317 (7167):1191-1194
54. Slooter GD, et al. (1999) Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer 81(5):767-771
55. SmithMC, et al. (2000) OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 62 (Suppl 1):69-72
56. Stoffel MP, et al. (2001) Radiation nephropathy after radiotherapy inmetastaticmedullary thyroid carcinoma. Nephrol Dial Transplant 16(5):1082-1083
57. Teunissen JJ, et al. (2004) Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22(13):2724-2729
58. Toth-Fejel S, Pommier RF (2004) Relationships among delay of diagnosis, extent of disease, and survival in patientswith abdominal carcinoid tumors. Am J Surg 187(5):575-579
59. Valkema R, et al. (2002a) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 32(2):110-122
60. Valkema R, et al. (2002b) Phase 1 study of therapy with 90YSMT487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors. J Nucl Med 43 (Suppl):33P (abstract
61. Valkema R, et al. (2003a) Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0,Tyr3)octreotide in patients with somatostatin receptor positive tumours. Eur J NuclMed 30 (Suppl 2):S232 (abstract
62. Valkema R, et al. (2003b) Survival in patients with neuroendocrine tumors after treatment with [90Y-DOTA,Tyr) in a phase-1 study. J Nucl Med 44 (Suppl 2):136P
63. Valkema R, et al. (2005) Long-termfollow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46 (1 Suppl):83-91
64. Van Eijck CH (2005) Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues. Br J Surg 92(11):1333-1334
65. van Putten JWG, et al. (2003) A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9(7):2472-2477
66. Virgolini I, et al. (2002) In-and Y-DOTA-lanreotide: Results and implications of the Mauritius trial. Semin Nucl Med 32(2):148-155
67. Waldherr C, et al. (2001) The clinical value of [90Y-DOTA]-dphe1-Tyr3- octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12(7):941-945
68. Waldherr C, et al. (2002a) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43(5):610-616
69. Waldherr C, et al. (2002b) Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29:S100 (abstract
70. Wild D, et al. (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30(10): 1338-1347
71. Yamada Y, et al. (1992) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 89(1):251-255
72. Yamada Y, et al. (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 195(2):844-852